Literature DB >> 11506959

Cell biological factors in ductal carcinoma in situ (DCIS) of the breast-relationship to ipsilateral local recurrence and histopathological characteristics.

A Ringberg1, L Anagnostaki, H Anderson, I Idvall, M Fernö.   

Abstract

All cases of ductal carcinoma in situ (DCIS) diagnosed from 1987 to 1991 in the Southern Health Care Region of Sweden, and operated upon with breast conserving treatment (BCT) with (n=66) or without (n=121) postoperative radiation (RT) were clinically followed, morphologically re-evaluated and analysed for cell biological factors (immunohistochemical assays or DNA flow cytometry). Median age at diagnosis was 58 years (range 29--83 years) and median follow-up was 62 months. Oestrogen (ER)- and progesterone receptor (PR)-negativity, c-erbB-2 overexpression, low bcl-2 expression, p53 accumulation, DNA non-diploidy and high Ki67, were strongly associated with high grade DCIS, and comedo-type necrosis. In contrast, significant associations to growth pattern (not diffuse versus diffuse) were seen only for c-erbB-2 and PgR. There was also a strong relationship between the cell biological factors, and a summary cell biological index based on principal component analysis was introduced (CBI-7). In the group that had not received postoperative RT, 31 ipsilateral local recurrences occurred (13 invasive, 18 DCIS). Ipsilateral recurrence-free interval (IL-RFI) was in univariate analyses significantly, or almost significantly, shorter for patients showing p53 accumulation, high Ki67 or low bcl-2, compared with patients with normal p53, low Ki67 and high bcl-2. The prognostic importance of the remaining cell biological factors was less pronounced. On the other hand, the index CBI-7, was a strong predictor for recurrence.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11506959     DOI: 10.1016/s0959-8049(01)00165-4

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  34 in total

1.  Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B-43.

Authors:  Kalliopi P Siziopikou; Stewart J Anderson; Melody A Cobleigh; Thomas B Julian; Douglas W Arthur; Ping Zheng; Eleftherios P Mamounas; Eduardo R Pajon; Robert J Behrens; Janice F Eakle; Nick C Leasure; James N Atkins; Jonathan A Polikoff; Thomas E Seay; Worta J McCaskill-Stevens; Rachel Rabinovitch; Joseph P Costantino; Norman Wolmark
Journal:  Breast Cancer Res Treat       Date:  2013-11-08       Impact factor: 4.872

Review 2.  Intratumoral Heterogeneity in Ductal Carcinoma In Situ: Chaos and Consequence.

Authors:  Vidya C Sinha; Helen Piwnica-Worms
Journal:  J Mammary Gland Biol Neoplasia       Date:  2018-09-07       Impact factor: 2.673

3.  Expression of CD151/Tspan24 and integrin alpha 3 complex in aid of prognostication of HER2-negative high-grade ductal carcinoma in situ.

Authors:  Hanna M Romanska; Piotr Potemski; Renata Kusinska; Janusz Kopczynski; Rafal Sadej; Radzislaw Kordek
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

4.  Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis.

Authors:  Karla Kerlikowske; Annette M Molinaro; Mona L Gauthier; Hal K Berman; Fred Waldman; James Bennington; Henry Sanchez; Cynthia Jimenez; Kim Stewart; Karen Chew; Britt-Marie Ljung; Thea D Tlsty
Journal:  J Natl Cancer Inst       Date:  2010-04-28       Impact factor: 13.506

5.  Potential use of vaccines in the primary prevention of breast cancer in high-risk patients.

Authors:  Matteo Lazzeroni; Davide Serrano
Journal:  Breast Care (Basel)       Date:  2012-08       Impact factor: 2.860

Review 6.  Next-generation sequencing: a powerful tool for the discovery of molecular markers in breast ductal carcinoma in situ.

Authors:  Hitchintan Kaur; Shihong Mao; Seema Shah; David H Gorski; Stephen A Krawetz; Bonnie F Sloane; Raymond R Mattingly
Journal:  Expert Rev Mol Diagn       Date:  2013-03       Impact factor: 5.225

7.  Prognosis for Survival of Young Women with Breast Cancer by Quantitative p53 Immunohistochemistry.

Authors:  David E Axelrod; Kinsuk Shah; Qifeng Yang; Bruce G Haffty
Journal:  Cancer Clin Oncol       Date:  2012

8.  Clinicopathologic, mammographic, and sonographic features in 1,187 patients with pure ductal carcinoma in situ of the breast by estrogen receptor status.

Authors:  Gaiane M Rauch; Henry M Kuerer; Marion E Scoggins; Patricia S Fox; Ana P Benveniste; Young Mi Park; Sara A Lari; Brian P Hobbs; Beatriz E Adrada; Savitri Krishnamurthy; Wei T Yang
Journal:  Breast Cancer Res Treat       Date:  2013-06-18       Impact factor: 4.872

Review 9.  Diagnosis and management of ductal carcinoma in situ.

Authors:  Amina Khan; Lisa A Newman
Journal:  Curr Treat Options Oncol       Date:  2004-04

Review 10.  The role of radiotherapy in the conservative treatment of ductal carcinoma in situ of the breast.

Authors:  Csaba Polgár; Zsuzsanna Kahán; Zsolt Orosz; Gabriella Gábor; Janaki Hadijev; Gábor Cserni; Janina Kulka; Nóra Jani; Zoltán Sulyok; György Lázár; Gábor Boross; Csaba Diczházi; Eva Szabó; Zsolt László; Zoltán Péntek; Tibor Major; János Fodor
Journal:  Pathol Oncol Res       Date:  2008-04-26       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.